Halozyme To Participate In The BMO 2020 Prescriptions For Success Healthcare Conference
Halozyme Therapeutics (NASDAQ: HALO) has announced that Dr. Helen Torley, the president and CEO, will participate in the BMO 2020 Prescriptions for Success Healthcare Conference. The virtual event will be held on June 23, 2020, at 3:00 p.m. ET / 12:00 p.m. PT. A live webcast will be available through the Investors section of Halozyme's website, with an archive accessible for 90 days after the event. Halozyme specializes in innovative solutions for drug delivery, significantly enhancing patient experiences and outcomes through their proprietary ENHANZE® technology.
- None.
- None.
SAN DIEGO, June 17, 2020 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that Dr. Helen Torley, president and chief executive officer, will be participating in the upcoming BMO 2020 Prescriptions for Success Healthcare Conference, which is being held as a virtual event. Dr. Torley will participate in a fireside chat at 3:00 p.m. ET / 12:00 p.m. PT on Tuesday, June 23, 2020.
A live webcast of each event can be accessed through the "Investors" section of Halozyme's website (www.halozyme.com), and an archive will be made available for 90 days following each event. To access a live webcast, please visit Halozyme's website approximately 15 minutes prior to the presentation to register and download any necessary audio software.
About Halozyme
Halozyme is a biopharmaceutical company bringing disruptive solutions to significantly improve patient experiences and outcomes for emerging and established therapies. Halozyme advises and supports its biopharmaceutical partners in key aspects of new drug development with the goal of improving patients' lives while helping its partners achieve global commercial success. As the innovators of the ENHANZE® technology, which can reduce hours-long treatments to a matter of minutes, Halozyme's commercially-validated solution has positively impacted more than 400,000 patient lives via four commercialized products across more than 100 global markets. Halozyme and its world-class partners are currently advancing multiple therapeutic programs intended to deliver innovative therapies, with the potential to improve the lives of patients around the globe. Halozyme's proprietary enzyme rHuPH20 forms the basis of the ENHANZE® technology and is used to facilitate the delivery of injected drugs and fluids, potentially reducing the treatment burden of other drugs to patients. Halozyme has licensed its ENHANZE® technology to leading pharmaceutical and biotechnology companies including Roche, Baxalta, Pfizer, Janssen, AbbVie, Lilly, Bristol-Myers Squibb, Alexion and argenx. Halozyme derives revenues from these collaborations in the form of milestones and royalties as the Company's partners make progress developing and commercializing their products being developed with ENHANZE®. Halozyme is headquartered in San Diego. For more information visit www.halozyme.com.
Contact:
Al Kildani
Vice President, Investor Relations and Corporate Communications
858-704-8122
ir@halozyme.com
!["Halozyme]("https://mma.prnewswire.com/media/75076/halozyme_therapeutics_logo.jpg" "\"Halozyme"){kind=logo}
!["Cision"]("https://c212.net/c/img/favicon.png?sn=LA38022&sd=2020-06-17" "\"Cision\"")
View original content to download multimedia:http://www.prnewswire.com/news-releases/halozyme-to-participate-in-the-bmo-2020-prescriptions-for-success-healthcare-conference-301079108.html
SOURCE Halozyme Therapeutics, Inc.
FAQ
What event is Halozyme participating in on June 23, 2020?
What time will Dr. Helen Torley's session start at the BMO conference?
Where can I access the live webcast for Halozyme's conference participation?
How long will the recording of the Halozyme conference presentation be available?
What is Halozyme's ENHANZE technology?
